In an era where remote collaboration is no longer optional but essential, Federica Fraschetti of MSD shared insights at CDMO Live 2025 on how to build high-performance virtual factory teams across sponsor and contract development and manufacturing partners. The session,
As the pharmaceutical landscape continues to face disruption from global events, supply chain volatility, and evolving regulatory expectations, the nature of partnerships between biopharma companies and CDMOs must evolve beyond transactional engagements. At CDMO Live 2025, Rocco Paracchini, Director at
Continuous manufacturing (CM) goes beyond a technical upgrade—it signals a strategic shift in how pharmaceutical manufacturing is planned and delivered. During CDMO Live 2025 in Rotterdam, Ray Sison, Managing Partner at SCxCMC, led a roundtable unpacking the real-world challenges, opportunities,
Fill and finish represents one of the most critical phases in pharmaceutical manufacturing—the process that bridges the gap between drug production and market deployment. This final manufacturing stage involves the precise filling of drug products into containers and preparing them
Small molecule active pharmaceutical ingredients (APIs) remain the backbone of the pharmaceutical industry. While the market for large molecule biologics is growing fast, in 2023 small molecule drugs accounted for approximately 60% of drugs (vs 40% biologics) currently on the
Clinical trial supply is a critical component of drug development, ensuring investigational medicinal products (IMPs) and materials reach research sites and patients with precision and compliance. As the backbone of clinical research, effective supply chain management directly impacts trial timelines,
Effective process development plays a key role in mitigating risk, accelerating time-to-market, and significantly reducing development costs for pharmaceutical companies. According to recent industry data, approximately 90% of drug candidates fail during development, with process-related challenges accounting for a significant
The clinical trials sector continues experiencing substantial growth, with investigational medicinal products (IMPs) serving as the cornerstone of pharmaceutical innovation and drug development. As regulatory frameworks evolve and breakthrough therapies advance through development pipelines, understanding the intricacies of IMP development,
Quality by Design (QbD) has revolutionised pharmaceutical manufacturing, transforming how companies approach drug development and production. As regulatory agencies increasingly emphasise science-based manufacturing approaches, implementing robust QbD principles has become essential for maintaining competitive advantage whilst ensuring patient safety. This
Viral vector manufacturing represents the sophisticated process of producing modified viruses that serve as delivery vehicles for therapeutic genetic material. These engineered vectors have revolutionised gene therapy applications, from treating rare genetic disorders to developing next-generation vaccines, including the COVID-19
